Appointment of New Directors


 

TIDMMDY 
 
RNS Number : 7469L 
MDY Healthcare PLC 
12 May 2010 
 

                               MDY Healthcare plc 
 
                          Appointment of New Directors 
 
 
12 May 2010: MDY Healthcare plc ("MDY Healthcare" or the "Company"), the 
strategic investor in healthcare companies, today announces the appointments of 
Mr Grahame Cook and Mr Martin Hunt as Non-executive Directors with immediate 
effect.  Derek Ablett, Non-executive Director, will retire from the MDY 
Healthcare board on 30 June 2010.  In June, the Company will be announcing its 
interim results for the six months ended 31 March 2010 and will update 
shareholders further at that time on the Company's strategy. 
 
Alan MacKay, Chairman, commented, "We are delighted to announce the appointment 
of two high calibre non-executives to the Board of MDY Healthcare. Both Grahame 
and Martin have significant sector experience and have an impressive track 
record of growing revenues for well-known organisations including Bristol-Myers 
Squibb and Sinclair Pharma. Their combined experience comes at an important 
stage in the Company's development and we look forward to updating shareholders 
on MDY's revised strategy at our interim results in June. 
 
"I would also like to take the opportunity to thank Derek Ablett for his 
contribution to the Company and wish him every success going forward. Derek has 
agreed to stay with the Company until 30 June 2010 to ensure a smooth transition 
and handover period." 
 
Grahame Cook is a chartered accountant and has more than 20 years' experience in 
investment banking in London, Switzerland and Germany. He was a director at 
Barclays de Zoete Wedd until 1995, then a Managing Director at UBS Investment 
Banking until 1998 following which he became CEO of West LB Panmure until 2003. 
 
Grahame has significant experience of capital raising, capital structuring and 
mergers and acquisitions. Since 2003, he has been a non-executive director of a 
number of companies, including Minoan Group plc, a resort developer, and 
Antisoma plc, a biotech company specialising in novel drugs for the treatment of 
cancer. Grahame is the chairman of Sinclair Pharma plc, a skin and mouth disease 
specialist and the chairman of Fulcrum Pharma PLC, a provider of strategic drug 
development and regulatory services. 
 
Martin Hunt has spent 28 years in the medtech industry working for both 
multi-nationals and small to medium size enterprises.  He spent 10 years at 
American Cyanamid in sales and marketing positions in the fields of 
pharmaceuticals, wound closure and latterly, ophthalmic surgery as marketing 
director for Europe, Middle East & Africa.  Martin spent five years at 
Bristol-Myers Squibb in wound care and stoma therapy as Regional Operations 
Director and then VP Sales, Europe between 1994 and 1996. 
 
Martin was a founder of a start-up in the IV infusion field before joining TSL, 
a company with a novel collagen-based technology, as CEO in 1999.  Under 
Martin's leadership, TSL was successfully admitted to AIM in 2001 and then sold 
to Covidien in 2008 at a substantial premium to the share price reflecting 
significant growth in revenues at TSL.  Since leaving TSL, Martin has continued 
to be involved in medtech innovations with a number of non-executive director 
and advisor roles.  These include Orthox Limited, an Oxford spin-out in the 
field of cartilage repair where he is chairman; Director and advisor at Trophos 
SA, a French biotech addressing CNS diseases; Programme Director at i4i (a 
National Institute for Health Research early stage medtech funding programme) 
and a Venture Partner at H2O Venture Partners in Oxford. 
 
Grahame David Cook, aged 52, is, or has been, a director or partner of the 
following companies during the previous five years: 
 
Current directorships/partnerships: 
 
+------------------------------+ 
| Antisoma plc                 | 
+------------------------------+ 
| Minoan Group plc             | 
+------------------------------+ 
| Australian Vineyards LLP     | 
+------------------------------+ 
| T J K Holdings LLP           | 
+------------------------------+ 
| T and J K Estates LLP        | 
+------------------------------+ 
| KS Halkins LLP               | 
+------------------------------+ 
| Sinclair Pharma plc          | 
+------------------------------+ 
| Kinnerton Street Freehold    | 
| Limited                      | 
+------------------------------+ 
| Davall Gears Ltd             | 
+------------------------------+ 
| Fulcrum Pharma plc           | 
+------------------------------+ 
 
Past directorships/partnerships: 
 
+------------------------------+ 
| Barclays Capital Finance     | 
| Limited                      | 
+------------------------------+ 
| Ebbgate Holdings Limited     | 
+------------------------------+ 
| Building & Property          | 
| (Holdings) Limited           | 
+------------------------------+ 
| Methuselah Life Markets      | 
| Limited                      | 
+------------------------------+ 
| BIW Technologies Limited     | 
+------------------------------+ 
| Methuselah Life Markets      | 
| Limited                      | 
+------------------------------+ 
| Lyceum Capital (Founders)    | 
| Limited                      | 
+------------------------------+ 
| Software Woking plc          | 
+------------------------------+ 
| Equity Holdings Limited      | 
+------------------------------+ 
| Parish Nominees Limited      | 
+------------------------------+ 
| Rectory Nominees Limited     | 
+------------------------------+ 
| St. Michael Nominees Limited | 
+------------------------------+ 
| Australian Vineyards Direct  | 
| Limited                      | 
+------------------------------+ 
| Trigen Holdings Limited      | 
+------------------------------+ 
| Trigen Limited               | 
+------------------------------+ 
| Ryes Capital (Founders) LLP  | 
+------------------------------+ 
 
There is no further information required to be disclosed pursuant to Schedule 2, 
paragraph (g) of the AIM Rules for Companies in connection with Mr Cook. 
 
Martin Braddock Hunt, aged 51, is, or has been, a director or partner of the 
following companies during the previous five years: 
 
Current directorships/partnerships: 
 
Orthox Limited 
Invictus Management Limited 
 
Past directorships/partnerships: 
 
Tissue Science Laboratories (UK) Limited 
Tissue Science Laboratories Limited 
Regentix Limited 
 
There is no further information required to be disclosed pursuant to Schedule 2, 
paragraph (g) of the AIM Rules for Companies in connection with Mr Hunt. 
 
 
For further information, please contact: 
 
+-------------------------------------------+---------------+ 
| MDY Healthcare plc                        |               | 
+-------------------------------------------+---------------+ 
| Alan MacKay, Chairman                     | +44 (0) 207   | 
|                                           | 647 1800      | 
+-------------------------------------------+---------------+ 
|                                           |               | 
+-------------------------------------------+---------------+ 
| Financial Dynamics                        |               | 
+-------------------------------------------+---------------+ 
| Ben Atwell, Susan Quigley                 | +44 (0) 207   | 
|                                           | 831 3113      | 
+-------------------------------------------+---------------+ 
| ben.atwell@fd.com, susan.quigley@fd.com   |               | 
+-------------------------------------------+---------------+ 
|                                           |               | 
+-------------------------------------------+---------------+ 
| Brewin Dolphin Limited (Nomad)            |               | 
+-------------------------------------------+---------------+ 
| Matt Davis                                | +44 (0) 845   | 
|                                           | 213 4730      | 
+-------------------------------------------+---------------+ 
 
 
Notes for editors: 
 
About MDY Healthcare 
MDY Healthcare plc is a sector specialised strategic investing company quoted on 
AIM (ticker symbol: MDY).  The Company seeks to achieve superior returns for 
shareholders by investing globally in companies, both public and private, across 
the healthcare sector.  The directors and executives have significant 
operational and investment experience in the sector and therefore the ability to 
identify and review a wide range of potential investments.  Further information 
can be found on the website www.mdyhealthcare.com. 
 
END 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAKKDDBOBKDNPD
MDY Healthcare (LSE:MDY)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024